Alnylam Pharmaceuticals Inc ALNY Phase 2 Diabetes Drug Progress and SP 500 Contender Status Lift Bullish Outlook BIPI BIP Perp latest quarterly filings offer no explicit earnings or operational performance details for investors MFC Manulife delivers 46 percent Q4 2025 EPS beat shares register small gains in todays session HPK HighPeak Energy reports far wider than expected Q4 2025 loss stock slips 016 percent today Target Corporation TGT Guggenheim Price Target Upgrade Confirms Accelerating Turnaround Momentum